Top Tweets for #ELCC2016

over 10 years ago

Studies Confirm Benefit of Plasma Genotyping to Predict Treatment Benefit in Patients With NSCLC https://t.co/7WetKI6OOp #ELCC2016 #LCSM

0

1

3

0

over 10 years ago

Pts w/EGFR-Expressing Non–Small Cell Lung Cancer Benefit Most From Necitumumab Added to Chemotherapy https://t.co/iNAwstshIN #LCSM #ELCC2016

0

1

2

0

KModyMD @kmody29

over 10 years ago

Pembro with promise in Small Cell Lung ca #ELCC2016 ...??portend responses in high grade GI NETs? https://t.co/ShbMeFrpjz

0

1

0

over 10 years ago

Dr. Raffaele Califano on Immunotherapy in Small-Cell Lung Cancer https://t.co/xQsoY4WeXr #ELCC2016

0

1

0

over 10 years ago

Dr. Suresh Ramalingam on Frontline Osimertinib in EGFR+ NSCLC https://t.co/UCbKNU6qXD #ELCC2016

0

2

1

0

over 10 years ago

Third-Generation EGFR TKIs Move to Frontline in Lung Cancer https://t.co/rRXVHnvzQe #ELCC2016

0

1

0

over 10 years ago

Update Identifies Best Responders to Necitumumab in NSCLC https://t.co/qpRHi0tayd #ELCC2016

0

1

0

over 10 years ago

Frontline Osimertinib Approaches 80% Response in EGFR+ NSCLC https://t.co/4bX7IOEgDf #ELCC2016

0

1

0

over 10 years ago

Dr. Paz-Ares on Connection of EGFR-Expression and Necitumumab Response in NSCLC https://t.co/am5a5e8QCK #ELCC2016

0

1

0

over 10 years ago

Dr. John Haanen on the Role of PD-L1 in Lung Cancer https://t.co/sl9AC7PROv #ELCC2016

0

1

0

over 10 years ago

Novel Vaccine Added to Chemotherapy Improves Patient Outcomes in Mesothelioma https://t.co/LgRTexy5GF #ELCC2016

0

1

0

over 10 years ago

High Response Rates Observed With BI-1482694 in T790M+ NSCLC https://t.co/kaxyvheApB #ELCC2016

0

2

1

0

over 10 years ago

Combined Durvalumab/Gefitinib Combo Shows Promise in EGFR-Mutated NSCLC https://t.co/39bU6V6xvX #ELCC2016

0

2

0

over 10 years ago

Immunotherapy With Live Bacterium Improves Response Rate In Malignant Pleural Mesothelioma https://t.co/mB5MW1Xv5X #ELCC2016 #LCSM

0

1

3

0